A phase 1 trial of imatinib, bevacizumab and metronomic cyclophosphamide in advanced colorectal cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase 1 trial of imatinib, bevacizumab and metronomic cyclophosphamide in advanced colorectal cancer
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 109, Issue 7, Pages 1725-1734
Publisher
Springer Nature
Online
2013-09-11
DOI
10.1038/bjc.2013.553
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity-Induced Tumor Regression
- (2012) J. C. Doloff et al. CANCER RESEARCH
- Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
- (2012) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer
- (2011) Hope S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going?
- (2011) Nicolas Penel et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas
- (2011) Shivaani Kummar et al. EUROPEAN JOURNAL OF CANCER
- Antiangiogenic and Radiation Therapy
- (2011) Ying Ren et al. INVESTIGATIVE RADIOLOGY
- Phase I Trials of Molecularly Targeted Agents: Should We Pay More Attention to Late Toxicities?
- (2011) Sophie Postel-Vinay et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
- (2010) Keith T. Flaherty et al. CANCER BIOLOGY & THERAPY
- Meta-analysis Shows That Detection of Circulating Tumor Cells Indicates Poor Prognosis in Patients With Colorectal Cancer
- (2010) Nuh N. Rahbari et al. GASTROENTEROLOGY
- Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer
- (2010) Alfonso Sánchez-Muñoz et al. ONCOLOGY
- Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents
- (2009) J. Tol et al. ANNALS OF ONCOLOGY
- Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer
- (2009) S. J. Cohen et al. ANNALS OF ONCOLOGY
- In Vivo Monitoring of Angiogenesis Inhibitory Treatment Effects by Dynamic Contrast-Enhanced Computed Tomography in a Xenograft Tumor Model
- (2009) Hans-Juergen Raatschen et al. INVESTIGATIVE RADIOLOGY
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
- (2008) G Allegrini et al. BRITISH JOURNAL OF CANCER
- Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy
- (2008) J. A. Blansfield et al. CLINICAL CANCER RESEARCH
- Dose Selection in Phase I Studies: Why We Should Always Go for the Top
- (2008) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
- (2008) Olwen M. Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)
- (2008) Axel Grothey et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer
- (2008) Steven J. Cohen et al. JOURNAL OF CLINICAL ONCOLOGY
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started